Hepatic impairment No dose adjustment is needed in individuals with delicate or reasonable (Boy or girl-Pugh A or B) hepatic impairment (see part five.2). Publicity to midostaurin and its active metabolite CGP62221 is significantly reduced in people with extreme hepatic impairment than that in people with regular hepatic function (see https://enricop520ejm3.tusblogos.com/profile